Skip to main content
. 2020 Jul 15;12(7):1905. doi: 10.3390/cancers12071905

Figure 7.

Figure 7

Comparative efficacy among the five therapeutic regimens (Niv+Ipi, Pem+PBC, Pem, Niv, and PBC) in terms of incidence of any Grade 3–5 drug-related adverse events (G3–5AEs) in the overall patient group. Comparisons were expressed as Treatment A versus Treatment B. Data are expressed in terms of odds ratio (OR) and 95% credible intervals (CrIs); Niv, nivolumab; PBC, platinum-based chemotherapy; Pem, pembrolizumab; Ipi, ipilimumab.